Injective Protocol Drives RWA Growth While INJ Eyes Key Target at $6.18

The use of real-world assets (RWA) in Injective Protocol is gaining escape velocity and quickly making it a prominent player in the world of decentralized finance. With Injective being the biggest Layer 1 scaling solution for public equity and commodities such as gold and silver, it gives its users unprecedented access to tokenized markets.

Source: Injective

Injective has also set the benchmark high with its introduction of pre-IPO stocks to the blockchain, including the tokenized shares of large companies such as OpenAI. While the future looks bright with expansion and innovations set to be developed, the most thrilling times for tokenized finance appear to be ahead, and the future looks bright indeed for this project.

Also Read: Injective (INJ) Price Forecast: Is $8 the Next Key Resistance in December?

INJ Price Shows Recovery After Surpassing 20 & 50 EMA

Technically, the recent price rise above the 20 EMA and 50 EMA, currently around $4.79, reveals continued resistance from the 100 EMA and 200 EMA levels. Furthermore, the candlestick charts have been showing persistent recovery attempts from the lower levels and small corrections around the resistance of the 100 EMA.

Source: TradingView

The Relative Strength Index (RSI) is at 57.6, which indicates moderate buying momentum, which is neither overbought nor oversold. The overall technical outlook reveals cautious optimism, as there is a positive trend in the shorter term, while there is still resistance at 100 EMA and a bearish trend overall until breaking above 200 EMA. A breakout above $4.87 can be awaited for further bullish verification.

INJ Builds Momentum and Sets Eyes on $5.16–$6.18 Range

However, the crypto analyst, Vexe, highlighted that following a long bearish market period, INJ appears to be exhibiting signs of a possible trend reversal, thereby providing a compelling long entry for swing traders. Positions have been initiated at the current market price with the intention of dollar-cost averaging at $4.578. The stop loss is placed at $4.304.

Source: Vexe

The targets have been specified: $5.16 for short-term gains, $5.69 for midterm gains, and $6.18 for long-term gains. Analysts point out that there is a smooth pattern, with an easy risk-reward ratio and high upside potential. Since market analysts believe there might be a potential reversal, INJ might hold high potential in terms of gaining considerable profits if the momentum continues.

Also Read: Injective Price Surge Incoming: INJ Could Hit $48 Soon